Myasthenia Gravis R&D Pipeline Analysis Report, Q4 2020
Myasthenia Gravis Pipeline Overview
The Q4 Myasthenia Gravis pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of drugs under development for Myasthenia Gravis, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.
Myasthenia Gravis Disease Types, Symptoms, Causes, and Available Treatment Options
The comprehensive report on the indication presents Myasthenia Gravis disease overview, Myasthenia Gravis types, Myasthenia Gravis symptoms, causes, and FDA/EMA approved treatment options.
Myasthenia Gravis Pipeline Trends and Insights
The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Myasthenia Gravis indication. The report presents near-term and long-term pipeline development trends and potential insights.
Myasthenia Gravis Company Trends and Insights
The report analyzes the development progress, current status, investments, partnerships, and other developments of 34 companies. Business profiles and contact details of the companies actively perusing Myasthenia Gravis pipeline are assessed.
Myasthenia Gravis R&D Pipeline Development Phase Trends and Insights
From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Myasthenia Gravis discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.
Small Myasthenia Gravis companies look for licensing and collaboration partners
High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Myasthenia Gravis pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.
Myasthenia Gravis Pipeline Market News and Developments during 2020
The Myasthenia Gravis industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.
Myasthenia Gravis Mechanism of Action and Targets
Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.
New molecular entity details
Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.
Sources and Research Methodology
Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.
Scope and Coverage
The Q4 Myasthenia Gravis pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of drugs under development for Myasthenia Gravis, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.
Myasthenia Gravis Disease Types, Symptoms, Causes, and Available Treatment Options
The comprehensive report on the indication presents Myasthenia Gravis disease overview, Myasthenia Gravis types, Myasthenia Gravis symptoms, causes, and FDA/EMA approved treatment options.
Myasthenia Gravis Pipeline Trends and Insights
The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Myasthenia Gravis indication. The report presents near-term and long-term pipeline development trends and potential insights.
Myasthenia Gravis Company Trends and Insights
The report analyzes the development progress, current status, investments, partnerships, and other developments of 34 companies. Business profiles and contact details of the companies actively perusing Myasthenia Gravis pipeline are assessed.
Myasthenia Gravis R&D Pipeline Development Phase Trends and Insights
From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Myasthenia Gravis discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.
Small Myasthenia Gravis companies look for licensing and collaboration partners
High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Myasthenia Gravis pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.
Myasthenia Gravis Pipeline Market News and Developments during 2020
The Myasthenia Gravis industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.
Myasthenia Gravis Mechanism of Action and Targets
Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.
New molecular entity details
Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.
Sources and Research Methodology
Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.
Scope and Coverage
- Myasthenia Gravis pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic candidates
- Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new molecular entity, area, and other details.
- Company-company partnerships, company-institute partnerships, and investment details of companies are included
- 34 companies are included including Ahead Therapeutics SL, Akari Therapeutics Plc, Alexion Pharmaceuticals Inc, Alpha Cancer Technologies Inc, Kashiv BioSciences LLC, Amplo Biotechnology Inc, AnTolRx Inc, Argenx SE, Bristol-Myers Squibb Co, Cabaletta Bio Inc, Cartesian Therapeutics Inc, Catalyst Pharmaceuticals, CuraVac Inc, Cytodyn Inc, DAS Therapeutics Inc, Grifols SA, HanAll Biopharma Co Ltd, KIMS Pharmaceutical Co Ltd, Kiniksa Pharmaceuticals Corp, Millennium Pharmaceuticals Inc, Momenta Pharmaceuticals Inc, Neurotune AG, Nihon Pharmaceuticals Co Ltd, NMD Pharma APS, Novartis Pharmaceuticals, Pfizer Inc, Protalex Inc, Ra Pharmaceuticals Inc, RemeGen Ltd, Takeda Pharmaceutical Co Ltd, Toleranzia AB, Tolerion Inc, UCB SA, Viela Bio Inc,
- Disease overview, Pipeline trends, market analysis, and other developments
- Potential licensing/new business opportunities in Myasthenia Gravis pipeline market
- Global coverage of companies and pipeline agents
- 2020 Trends, market analysis, and developments
- Potential growth opportunities
- Comprehensive details of drug candidates
- Drive pipeline research and commercial assessment
- Assess most promising drug candidates and stay ahead of the competition
- Strengthen your pipeline through identifying business expansion and acquisition opportunities
- Develop new candidates based on most focused targets and mechanism of actions
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. MYASTHENIA GRAVIS PIPELINE TRENDS AND INSIGHTS
2.1 Dominant Phase type of Myasthenia Gravis Pipeline, 2020
2.2 Most focused Mechanism of Action in Myasthenia Gravis Pipeline
2.3 Leading type of Route of Administration during 2020
2.4 Proportion of New Molecular Entities in Myasthenia Gravis pipeline
2.5 Active Companies Developing Myasthenia Gravis pipeline
3. MYASTHENIA GRAVIS DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS
3.1 Disease Overview
3.2 Types
3.3 Symptoms
3.4 Approved Treatment Options
4. MYASTHENIA GRAVIS PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS
4.1 Ahead Therapeutics SL
Akari Therapeutics Plc
Alexion Pharmaceuticals Inc
Alpha Cancer Technologies Inc
Kashiv BioSciences LLC
Amplo Biotechnology Inc
AnTolRx Inc
Argenx SE
Bristol-Myers Squibb Co
Cabaletta Bio Inc
Cartesian Therapeutics Inc
Catalyst Pharmaceuticals
CuraVac Inc
Cytodyn Inc
DAS Therapeutics Inc
Grifols SA
HanAll Biopharma Co Ltd
KIMS Pharmaceutical Co Ltd
Kiniksa Pharmaceuticals Corp
Millennium Pharmaceuticals Inc
Momenta Pharmaceuticals Inc
Neurotune AG
Nihon Pharmaceuticals Co Ltd
NMD Pharma APS
Novartis Pharmaceuticals
Pfizer Inc
Protalex Inc
Ra Pharmaceuticals Inc
RemeGen Ltd
Takeda Pharmaceutical Co Ltd
Toleranzia AB
Tolerion Inc
UCB SA
Viela Bio Inc
5. MYASTHENIA GRAVIS PIPELINE DRUG PROFILES
5.1 Current Status of Drug and Vaccine Candidates
5.2 Drug Snapshot
5.2.1 Drug
5.2.2 Mechanism of Action
5.2.3 Phase
5.2.4 Co-Developer
5.2.5 Originator
5.2.6 Synonym
5.2.7 Route of Administration
5.2.8 Type of Molecule
5.2.9 Orphan Drug Status
5.2.10 New Molecular Entity
5.2.11 Area
5.3 Drug Details
5.4 Mechanism of Action
5.5 Licensing/Collaboration Agreements
5.6 Clinical Trial Details
6. MYASTHENIA GRAVIS PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020
7. APPENDIX
7.1 About the Publisher
7.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2. MYASTHENIA GRAVIS PIPELINE TRENDS AND INSIGHTS
2.1 Dominant Phase type of Myasthenia Gravis Pipeline, 2020
2.2 Most focused Mechanism of Action in Myasthenia Gravis Pipeline
2.3 Leading type of Route of Administration during 2020
2.4 Proportion of New Molecular Entities in Myasthenia Gravis pipeline
2.5 Active Companies Developing Myasthenia Gravis pipeline
3. MYASTHENIA GRAVIS DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS
3.1 Disease Overview
3.2 Types
3.3 Symptoms
3.4 Approved Treatment Options
4. MYASTHENIA GRAVIS PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS
4.1 Ahead Therapeutics SL
Akari Therapeutics Plc
Alexion Pharmaceuticals Inc
Alpha Cancer Technologies Inc
Kashiv BioSciences LLC
Amplo Biotechnology Inc
AnTolRx Inc
Argenx SE
Bristol-Myers Squibb Co
Cabaletta Bio Inc
Cartesian Therapeutics Inc
Catalyst Pharmaceuticals
CuraVac Inc
Cytodyn Inc
DAS Therapeutics Inc
Grifols SA
HanAll Biopharma Co Ltd
KIMS Pharmaceutical Co Ltd
Kiniksa Pharmaceuticals Corp
Millennium Pharmaceuticals Inc
Momenta Pharmaceuticals Inc
Neurotune AG
Nihon Pharmaceuticals Co Ltd
NMD Pharma APS
Novartis Pharmaceuticals
Pfizer Inc
Protalex Inc
Ra Pharmaceuticals Inc
RemeGen Ltd
Takeda Pharmaceutical Co Ltd
Toleranzia AB
Tolerion Inc
UCB SA
Viela Bio Inc
5. MYASTHENIA GRAVIS PIPELINE DRUG PROFILES
5.1 Current Status of Drug and Vaccine Candidates
5.2 Drug Snapshot
5.2.1 Drug
5.2.2 Mechanism of Action
5.2.3 Phase
5.2.4 Co-Developer
5.2.5 Originator
5.2.6 Synonym
5.2.7 Route of Administration
5.2.8 Type of Molecule
5.2.9 Orphan Drug Status
5.2.10 New Molecular Entity
5.2.11 Area
5.3 Drug Details
5.4 Mechanism of Action
5.5 Licensing/Collaboration Agreements
5.6 Clinical Trial Details
6. MYASTHENIA GRAVIS PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020
7. APPENDIX
7.1 About the Publisher
7.2 Sources and Research Methodology
